Loading…
Loading…
Health Canada NOC enables treatment for porphyria, metabolic disorder Health Canada NOC enables treatment for porphyria, metabolic disorder
PALO ALTO, Calif.--(BUSINESS WIRE)--GondolaBio, a clinical-stage biopharmaceutical company developing novel medicines for patients living with genetic diseases, on behalf of its affiliate Portal Therapeutics, today announced positive data from its Phase 2a GATEWAY trial of PORT-77 in patients with erythropoietic protoporphyria (EPP). PORT-77 is a novel investigational oral, small molecule ABCG2 inhibitor designed to treat EPP and X-linked protoporphyria (XLP), two rare genetic disorders charact.
Japan spent about $73 billion on foreign exchange intervention and the Bank of Japan has raised rates, but the yen remains near 160 against the dollar. A wide U.S.-Japan rate gap, carry trades and Prime Minister Sanae Takaichi's reflationary stance continue to weigh on the currency.
WATERTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the launch of an expanded access program (EAP) for bitopertin for eligible patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) in the U.S.
Disc Medicine NASDAQ: IRON Chief Executive Officer John Quisel said patient demand for the company's bitopertin program in erythropoietic protoporphyria, or EPP, remains strong after the company enrolled 183 patients in the APOLLO confirmatory study, above its original target of 150.
Investors are focusing on AI developments in North Asia. China is coming out of more than three years of deflation measured by the producer price index.
Asia-Pacific equities outside Japan have quietly delivered one of the stronger performances among developed-market ETFs over the past year, and most retirees haven't noticed.
JPMorgan Chase and Co. cut its stake in iShares MSCI Pacific ex Japan ETF (NYSEARCA:EPP) by 2.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,912,109 shares of the company's stock after selling 197,114 shares during the quarter. JPMorgan